CEFPIROME IN THE SURGICAL FIELD

• Published in: CHEMOTHERAPY Vol. 39; no. Supplement1; pp. 336 - 346
• Main Author: FURUHATA, HISASHI
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1991
• Subjects: Cefpirome
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.39.Supplement1_336

We performed basic and clinical studies on cefpirome (CPR), a new cephalosporin, and obtained the following results. The antibacterial activity of CPR against clinical isolates was compared with those of ampicillin (ABPC), piperacillin (PIPC), aspoxicillin (ASPC), cefazolin (CEZ), cefuroxime (CXM), cefoperazone (CPZ), cefotiam (CTM), cefotaxime (CTX), ceftizoxime (CZX), cefpiramide (CPM), ceftazidime (CAZ), cefoxitin (CFX), cefmetazole (CMZ), cefotetan (CTT), latamoxef (LMOX), imipenem (IPM), tobramycin (TOB) and minocycline (MINO). Its activity against methicillin-resistant Staphylococcus aureus (MRSA) was also compared with those of cloxacillin (MCIPC), amoxicillin (AMPC), cephalothin (CET), cephaloridine (CER), cefamandole (CMD), flomoxef sodium (FMOX), cefepime (BMY-28142), ofloxacin (OFLX), tosufloxacin (TFLX), netilmicin (NIL), vancomycin (VCM), and fosfomycin (FOM). The MICs of CPR were studied against clinical isolates such as coagulase-positive staphylococci (CPS), coagulase-negative staphylococci (CNS), Escherichia coli, Klebsiella pneumoniae. Enterobacter cloacae, Pseudomonas aeruginosa and MRSA. CPR showed excellent activity against E. coli and K. pneumoniae, and good activity against E. cloacae, but it was slightly less active against P. aeruginosa and MRSA. In the clinical study, CPR was administered to nine patients with mainly intra-abdominal infections. Clinical response was fairly good in eight cases and fair in one case. No serious side effects were noted.